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Chemokine ligand 2 (CCL2) binds to its receptor C–C chemokine
receptor 2 (CCR2), initiating tissue inflammation, and recent
studies have suggested a beneficial effect of a blockade of
this pathway in diabetic nephropathy. To investigate the
mechanism of protection, we studied the effect of RS504393,
a CCR2 antagonist, on insulin resistance and diabetic
nephropathy in db/db mice. Administering this antagonist
improved insulin resistance as confirmed by various
biomarkers, including homeostasis model assessment index
levels, plasma insulin levels, and lipid abnormalities. Mice
treated with the antagonist had a significant decrease in
epididymal fat mass as well as phenotypic changes of
adipocytes into small differentiated forms with decreased
CCL2 expression and lipid hydroperoxide levels. In addition,
treatment with the CCR2 antagonist markedly decreased
urinary albumin excretion, mesangial expansion, and
suppressed profibrotic and proinflammatory cytokine
synthesis. Furthermore, the CCR2 antagonist improved lipid
metabolism, lipid hydroperoxide, cholesterol, and triglyceride
contents of the kidney, and decreased urinary 8-isoprostane
levels. Hence, our findings suggest that CCR2 antagonists can
improve insulin resistance by modulation of the adipose
tissue and restore renal function through both metabolic and
anti-fibrotic effects in type 2 diabetic mice.
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Diabetes is the most common cause of end-stage renal disease
and is responsible for the increasing morbidity and mortality
rates due to cardiovascular diseases in many countries. The
kidney is the main target organ involved in the major critical
complications caused by diabetes mellitus.1 Although a
pathogenic mechanism to explain the progression of diabetic
nephropathy has not yet been elucidated, inflammatory
mechanisms have been suggested to contribute to the
progression of diabetic nephropathy.2,3
Chemokines have important roles in the recruitment of
inflammatory cells to the kidney. Increased infiltration of
monocytes and macrophages has been observed in the
glomeruli and interstitium of the diabetic kidney in human
and animal studies.4–7 Although the exact cellular and
molecular mechanisms for the recruitment of monocytes
and macrophages to the kidney remain uncertain, chemo-
kines and their receptors have been shown to be involved in
the diabetic renal injury process.8,9
Chemokine ligand 2 (CCL2), also known as monocyte
chemoattractant protein-1, is a member of the C–C motif
family of chemokines and has been reported to have an
important role in the pathogenesis of diabetic nephropathy.8
C–C chemokine receptor 2 (CCR2), a seven-transmembrane
protein-coupled receptor, is a receptor for CCL2 and is
expressed by monocytes. Importantly, local recruitment of
monocytes is considered to be the predominant mechanism
by which CCL2 contributes to renal damage. Indeed, several
recent reports have shown that both CCL2 and CCR2 are
responsible for the inflammatory process in diabetic
nephropathy.10–12 CCL2 is produced in intrinsic renal cells,
including mesangial cells, podocytes, and tubular cells.13–15
Insulin resistance is considered to have a central role in the
development of metabolic disorders, such as obesity and
diabetes mellitus.16 In terms of insulin resistance, the adipose
tissue has recently been proposed to be a pivotal organ,
whereby the inflammatory process in this tissue serves as a
central axis for the development of insulin resistance.17
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Indeed, it is now believed that the adipose tissue can function
as an endocrine organ, secreting a large number of bioactive
proteins known as adipocytokines, which have essential roles
in glucose and lipid metabolism, insulin resistance, inflam-
mation, and atherosclerosis.18 The CCL2/CCR2 pathway was
recently proposed to be involved in adipose tissue inflamma-
tion and insulin resistance,19 however, the physiological
action of CCR2 inhibition in the adipose tissue remains
uncertain.
In this study, we investigated the effect of the CCR2
antagonist RS504393 on insulin resistance under the
hypothesis that inhibition of CCR2 may improve insulin
resistance through modulation of the adipose tissues in
db/db mice. We also examined the effects of this CCR2
antagonist on diabetic nephropathy, looking specifically at
renal inflammation and renal lipid metabolism in type 2
diabetic mice.
RESULTS
Biochemical and physical parameters in experimental
animals
As chemokines and their receptors have been shown to be
important for the development of diabetic target organ
injury, we measured various biochemical and physical
parameters. Table 1 shows the various biochemical results
obtained for each experimental group of animals. There was
no significant difference in body weight, water intake, HbA1c
level, and organ masses such as the heart, liver, and kidney
between the two groups; however, fasting blood glucose level
and epididymal fat mass were significantly decreased in the
CCR2 antagonist-treated group. Unexpectedly, 24-h urine
volume was significantly higher in the CCR2 antagonist-
treated group between 8 and 12 weeks than in controls.
Plasma levels of sodium or potassium, CCL2, and aldoster-
one were not significantly different between the two groups.
Although there was no statistical difference in systolic blood
pressure, fractional shortening reflecting systolic cardiac
function, and left ventricular (LV) hypertrophy, the CCR2
antagonist-treated group showed improvement in these
parameters. Interestingly, serum creatinine concentration was
significantly decreased in the CCR2 antagonist group than in
controls. Furthermore, as shown in Figure 1, urinary albumin
excretion was significantly decreased after CCR2 antagonist
treatment even after 1 month of treatment, and the anti-
albuminuric effects of CCR2 antagonist treatment were
observed persistently throughout the entire study period.
Taken together, these findings suggest that the CCR2 antagonist
protects diabetic target organ injury including the heart,
adipose tissue, and kidney in type 2 diabetic mice.
Effects of CCR2 antagonist treatment on metabolic
parameters in db/db mice
As CCR2 regulates inflammatory responses and influences
metabolic effect including systemic glucose homeostasis, we
next measured various metabolic parameters. We first
examined whether the CCR2 antagonist could alter insulin
resistance in db/db mice. As shown in Figure 2a and b, the
improvement in insulin resistance and glucose intolerance by
RS504393 treatment was confirmed by an intraperitoneal
(i.p.) insulin tolerance test and an i.p. glucose tolerance test.
Although the basal levels of fasting blood glucose were
slightly lower in the RS504393-treated group, the insulin
tolerance test clearly demonstrated improved insulin resis-
tance in RS504393-treated mice vs that of controls.
Table 1 | Biochemical and physical parameters in experimental animals
0 4 8 12
Time (weeks) Control RS504393 Control RS504393 Control RS504393 Control RS504393
BW (g) 38.9±0.80 38.3±0.67 55.9±1.38 51.1±2.05 61.3±2.25 59.3±2.86 63.7±3.32 61.4±3.70
UV (ml) 2.60±0.38 3.50±0.44 3.61±0.85 3.41±1.89 3.09±0.59 5.42±1.19a 3.66±0.48 5.34±0.47a
FBG (mg/dl) 303.8±22.3 320.5±40.9 482.4±46.4 345.5±41.0a 531.4±50.6 539.5±76.2 487.1±51.6 372.5±30.3a
HbA1c (%) NA NA 8.80±0.30 7.68±0.35 8.90±0.50 8.59±0.56 8.57±0.36 8.45±0.46
Adiponectin (mg/ml) NA NA NA NA NA NA 89.2±7.91 106.4±10.71
CCL2 (ng/ml) NA NA NA NA NA NA 496.7±37.2 590.5±31.9
Water intake (ml) NA NA 12.5±1.64 8.27±0.73 11.0±0.53 11.7±0.83 14.5±1.17 13.9±2.02
Food intake (g) NA NA 5.79±0.13 4.86±0.19 6.06±0.22 5.36±0.13 6.69±0.16 5.61±0.28a
SBP (mmHg) NA NA NA NA NA NA 127.7±12.6 115.6±21.3
FS (%) NA NA NA NA NA NA 45.04±3.69 49.27±1.97
LVMI (mg per 10 gBW) NA NA NA NA NA NA 36.95±5.63 27.38±3.32
P-Cr (mg/dl) NA NA NA NA NA NA 0.64±0.03 0.52±0.03b
P-Na (mequiv./l) NA NA NA NA NA NA 145.8±2.37 146.1±1.47
P-K (mequiv./l) NA NA NA NA NA NA 4.06±0.15 4.30±0.17
P-aldo (pg/ml) NA NA NA NA NA NA 269.2±76.1 150.8±52.8
Kidney/BW NA NA NA NA NA NA 0.71±0.09 0.79±0.08
Heart/BW NA NA NA NA NA NA 0.29±0.05 0.30±0.02
Fat/BW NA NA NA NA NA NA 6.26±0.63 4.98±0.34a
Liver/BW NA NA NA NA NA NA 5.98±0.20 5.85±0.35
Abbreviations: BW, body weight; CCL2, chemokine ligand 2; FBG, fasting blood glucose; FS, fractional shortening; HbA1c, hemoglobin A1c; LVMI, left ventricular mass index;
NA, not applicable; P-aldo, plasma aldosterone; P-Cr, plasma creatinine; P-K, plasma potassium; P-Na, plasma sodium; SBP, systolic blood pressure; UV, urine volume.
Organ mass is expressed as percentage of body weight. Values are expressed as mean±s.e.m. Statistical analysis was performed between groups at the same time periods.
aPo0.05, control vs RS504393.
bPo0.01, control vs RS504393.
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In accordance with improved insulin resistance, RS504393
treatment significantly decreased plasma total cholesterol
and triglyceride levels (cholesterol, controls; 160.7±8.3,
RS504393; 116.7±8.3, Po0.01; triglyceride, controls;
142.8±12.6, RS504393; 106±10.5, Po0.05) (Figure 2c).
In addition, plasma insulin levels and homeostasis model
assessment-insulin resistance were significantly higher in
control mice than in RS504393-treated mice (insulin,
controls; 6.45±0.95, RS504393; 1.96±0.23, Po0.01;
homeostasis model assessment-insulin resistance, controls;
7.71±1.03, RS504393; 2.21±0.21, Po0.01) (Figure 2d and
e). Finally, although plasma adiponectin levels were higher in
RS504393-treated animals than in controls, the difference did
not reach statistical difference (Table 1). These results suggest
that the CCR2 antagonist improves insulin resistance and
lipid abnormalities observed in diabetic mice.
Effects of the CCR2 antagonist on histological changes of
various organs in db/db mice
We next investigated the effect of CCR2 inhibition in db/db
mice on histological changes in various organs such as the
kidney, heart, aorta, liver, pancreas, and adipose tissue after
RS504393 treatment for 3 months. Figure 3 shows the
representative renal pathology in experimental animals
(Supplementary Figure S3 online). Consistent with marked
attenuation of albuminuria, mesangial expansion and
glomerulosclerotic changes were markedly improved in the
RS504393 treatment group (Figure 3). Figure 4 shows the
representative histological changes in the other organs
(Supplementary Figure S4 online). Interestingly, RS504393
treatment resulted in a significant improvement in islet
hypertrophy of the pancreases of these animals (Figure 4a
and f). In addition, RS504393 treatment improved the level
of fat accumulation in the livers and medial hyperplasia in
the aorta, but did not significantly alter the amount of
fibrotic change in cardiac tissues (Figure 4g and h). In
addition, it was interesting to note that the adipose tissue
obtained from epididymal fat showed that RS504393
treatment induced phenotypic changes in adipocytes, causing
differentiation into small adipocytes (Figure 4d and i).
Furthermore, this phenotypic change was consistent with the
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Figure 1 | Effects of RS504393 on 24-h urinary albumin
excretion in experimental animals. Twenty-four-hour urine was
collected at monthly intervals after RS504393 administration. Data
shown are means±s.e.m.; *Po0.05 and **Po0.01, control vs
RS504393.
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Figure 2 | Effects of RS504393 on insulin resistance, glucose intolerance, and metabolic parameters in experimental animals.
(a) Insulin tolerance test, (b) glucose tolerance test (GTT), (c) plasma lipid concentrations, (d) plasma insulin concentrations, and (e) HOMA-IR.
Data in GTT were expressed as percentage of basal glucose levels due to high basal glucose levels. Data shown are means±s.e.m. HOMA-IR,
the homeostasis model assessment index, was calculated using the equation fasting glucose (mmol/l) fasting insulin (mUnits/l)/22.5.
Comparisons were performed between control groups and the RS504393 treatment group at the same time points; *Po0.05, control vs
RS504393; **Po0.01, control vs RS504393. HOMA-IR, homeostasis model assessment-insulin resistance.
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Figure 3 |Representative renal histological findings in experimental animals. (a1–a2) PAS stain; (b1–b2) MT stain; (c) mesangial
expansion score; (panels a1, b1) control db/db mice; (panels a2, b2) db/db mice treated with RS504393; short arrows show (panel a1)
typical mesangial expansion area and (panel b1) MT (þ ) sclerotic area. Data shown are means±s.e.m.; **Po0.01, control vs RS504393.
Original magnification  400. MT, Masson’s trichrome; PAS, periodic acid-Schiff.
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Figure 4 |Representative histological findings of various organs in experimental animals. (a1–a2) Pancreas, PAS stain, (b1–b2)
liver, HE stain, (c1–c2) aorta, HE stain, (d1–d2) fat, HE stain, (e1–e2) heart, MT stain. (f–h) Quantitative analysis of (panel f) islet cell mass,
(panel g) lipid content in the liver, (panel h) aorta intimal/medial ratio, and (panel i) adipocyte size. (Panels a1–e1) control db/db mice;
(panels a2–e2) db/db mice treated with RS504393. Islet cell mass, adipocyte size, and aorta intimal/medial ratio are expressed as percentage
value relative to control group; short arrows show (panel a1) enlarged islet cell mass, (panel b1) typical fat accumulation, (panel c1) medial
thickness area, and (panel d1) enlarged adipocyte. Data are shown as means±s.e.m.; *Po0.05, control vs RS504393; **Po0.01, control vs
RS504393. Original magnification  400. HE, hematoxylin and eosin; MT, Masson’s trichrome; PAS, periodic acid-Schiff.
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change in epididymal fat mass decreased by RS504393
treatment. These results imply that the CCR2 antagonist
improves structural alterations of various target organs
induced by diabetic condition.
Anti-inflammatory effects of the CCR2 antagonist on the
kidney and adipose tissue
As the CCR2 antagonist markedly improved renal functional
and structural changes, and induced phenotypic change
associated with insulin resistance, we next evaluated the
molecular mechanism of CCR2 inhibition in the kidney and
adipose tissue in experimental animals. We examined the
expression of profibrotic or proinflammatory molecules,
such as transforming growth factor (TGF)-b1, type IV
collagen, plasminogen activator inhibitor-1 (PAI-1), and
CCL2. As shown in Figure 5a, RS504393 treatment
significantly suppressed the expression of profibrotic or
proinflammatory molecules in the kidney. Figure 6 shows
representative immunohistochemical staining for PAI-1, type
IV collagen, TGF-b1, and CD68 (Supplementary Figure S6
online). Consistent with mRNA expression analysis, immu-
nostaining scores for these markers were significantly
decreased by RS504393 treatment. In addition, the renal
infiltration of monocytes/macrophages as measured by CD68
staining was attenuated by RS504393 treatment in diabetic
kidneys. On the other hand, in the adipose tissue, the
expressions of CCL2 and PAI-1 were found to be significantly
inhibited by RS504393 treatment. Finally, the expressions of
peroxisome proliferator-activated receptor-g and adiponectin
showed increasing trends with RS504393 treatment, although
the changes were not statistically significant (Figure 5b).
Effects of the CCR2 antagonist RS504393 on lipid
peroxidation and lipid metabolism in the kidneys and
adipose tissues
As RS504393 treatment improved albuminuria and insulin
resistance and was associated with improvements in systemic
metabolic abnormalities, we next examined whether the
improvement in renal function was derived from correction
of alteration of renal lipid metabolism. In particular, we
measured mRNA expression levels of genes known to be
involved in lipid synthesis and cholesterol efflux. As shown in
Figure 7a, the gene expression for sterol-regulatory element-
binding protein-1c (SREBP-1c), which induces cholesterol
synthesis, was dramatically downregulated by RS504393
treatment. Meanwhile, the gene expression for ABCA-1
(adenosine triphosphate-binding cassette transporter A1),
which modulates cholesterol efflux, was significantly upre-
gulated by RS504393 treatment. However, there were no
significant changes in gene expression of the 3-hydroxy-3-
methylglutaryl-coenzyme A reductase or farnesoid X recep-
tor. In accordance with these findings, renal cholesterol and
triglyceride levels were significantly decreased by RS504393
treatment (Figure 7b and c); however, there were no
significant changes in cholesterol and triglyceride contents
in the adipose tissues (Figure 7d and e). As RS504393
treatment most profoundly suppressed SREBP-1c expression,
we performed western blot analysis from the renal cortical
tissues to further confirm the change of SREBP-1c. As shown
in Figure 7f, the active cleaved form of the SREBP-1 protein
(p68) was markedly suppressed by RS504393 treatment. In
addition, we further evaluated whether RS504393 treatment
was associated with lipid peroxidation and oxidative stress in
the kidneys and adipose tissues. As oxidative stress in diabetic
milieu causes the peroxidation of lipids and leads to cellular
dysfunction including inhibition of metabolism, we also
evaluated the changes of lipid hydroperoxide (LPO) and
8-isoprostane that is one of the most common by-products of
lipid peroxidation: In particular, we measured LPO levels of
tissues and 8-isoprostane levels of plasma and urine.
Interestingly, LPO levels in the kidney and adipose tissues
were significantly suppressed by RS504393 treatment
(Figure 8a and b). Furthermore, plasma and urinary
8-isoprostane levels were markedly decreased by RS504393
treatment, which was consistent with LPO results (Figure 8c
and d). Taken together, these results suggest that the CCR2
antagonist improves oxidative stress in the kidney and
adipose tissue, and that the improvement in renal function
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Figure 5 | Effects of RS504393 on mRNA expression for proinflammatory and profibrotic cytokines in the renal and adipose tissues
in experimental animals. (a) Gene expression in the renal cortical tissues. (b) Gene expression in the adipose tissues. Data are shown as
means±s.e.m. *Po0.05, control vs RS504393; **Po0.01, control vs RS504393; ***Po0.001, control vs RS504393. MCP-1; monocyte
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was also derived from correction of alteration of renal lipid
metabolism.
Effects of the CCR2 antagonist RS504393 on adipocyte
differentiation and 2-DOG uptake in cultured adipocytes
As an in vivo study demonstrated that RS504393 treatment
induced phenotypic changes in adipocytes, we further
evaluated the direct effect of RS504393 on insulin resistance
using oil-red O staining and 2-deoxyglucose uptake assay.
Interestingly, RS504393 treatment resulted in an increase in
differentiated adipocytes containing intracytoplasmic lipid
accumulation (Figure 9a). As shown in Figure 9b, insulin
treatment markedly increased glucose uptake, and RS504393
treatment significantly further increased insulin-induced
2-DOG (2-deoxy-D-glucose) uptake in adipocytes (Supple-
mentary Figure S9 online).
DISCUSSION
Among the many potential pathogenetic mechanisms
responsible for the development of diabetic kidney disease,
an inflammation mechanism has been suggested to have a
role in the development of diabetic nephropathy.2,3,6 Indeed,
urinary CCL2 excretion increases in patients with early
diabetic nephropathy, and acute-phase markers of inflamma-
tion are associated with the nephropathy state in type 2
diabetic patients.20,21
In this study, we observed that altered morphological
changes in diabetes were improved by treatment with a CCR2
antagonist in various target organs, such as the pancreas,
liver, and aorta. These results were in agreement with a recent
report that propageramanium, another CCR2 antagonist,
improves insulin resistance and hepatic steatosis in db/db
mice.22 In fact, insulin resistance contributes to the develop-
ment of hepatic steatosis through an impaired inhibitory
effect of insulin on lipolysis, leading to increased delivery of
free-fatty acids in the liver.23 Interestingly, we found that a
CCR2 blockade improved islet cell hyperplasia in the
pancreas, reduced medial thickness in the aortic wall
associated with improvement in insulin resistance. On the
other hand, we were unable to discern any significant
functional and structural improvements in cardiac tissues
after CCR2 inhibition. There is a great deal of evidence
4
PAI-1
10
3
Type IV collagen
TGFβ1 8
*
6
2
** 4
**
Im
m
u
n
o
st
ai
ni
ng
 s
co
re
1 ** 2
0
Control RS504393
CD
68
-p
os
itiv
e
 c
e
lls
/g
lo
m
er
u
lu
s
0
Control RS504393
a1 b1 b2a2
c1
e f
d1 d2c2
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implicating the role of CCL2 in human and experimental
atherosclerosis.24–26 Thus, the improved medial hyperplasia
observed in this study may have been derived from a direct
effect of CCR2 inhibition on vascular smooth muscle cells or
an improvement in insulin resistance.
The above findings raised the question of how a CCR2
antagonist could improve insulin resistance. There is
increasing evidence indicating that insulin resistance is
associated with systemic inflammation.27–30 Indeed, increased
levels of inflammatory markers such as C-reactive protein,
SREBP-1c
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Figure 7 | Effects of RS504393 on lipid metabolism in experimental animals. (a) mRNA expression for renal lipid metabolism in the renal
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interleukin-6, and PAI-1 seem to be related to the
incidence of type 2 diabetes, and multifactorial intervention
in diabetic patients reduces inflammatory markers.31 As
one of the important sources of systemic inflammation,
the adipose tissue has emerged as an important factor in
this process, as adipocytes can secrete large numbers of
cytokines and chemokines that can then exert negative or
positive effects on insulin resistance.32–34 In addition, previous
studies have also suggested that inflammatory changes in the
adipose tissue contribute to the development of insulin
resistance.35,36 Recently, the CCL2/CCR2 pathway has been
suggested to be involved in adipose tissue inflammation and
insulin resistance.37,38
In this study, we found that plasma levels of insulin and
homeostasis model assessment-insulin resistance were sig-
nificantly decreased and that these changes were accompa-
nied by lipid abnormalities. However, HbA1c levels did not
show significant differences and the 24-h urine volume was
rather significantly increased by CCR2 antagonist treatment.
Although the reason for the difference between fasting blood
glucose and HbA1c level is not clear, HbA1c levels may be
affected by several factors, such as erythrocyte life span, iron
deficiency, hemoglobin glycation rate, and renal function. It
may be possible that some of these factors induce the
discrepant results between fasting blood glucose and HbA1c.
With regard to urine volume, there are several reports that
proinflammatory cytokines induce vasopressin secretion.39
Although it is not clear why the CCR2 antagonist group
showed higher urine volume in spite of better glycemic
control, inhibition of proinflammatory cytokines by the
CCR2 antagonist may decrease vasopressin levels, leading to
higher urine output.
It is interesting that CCR2 inhibition significantly
decreased epididymal fat masses and induced phenotypic
changes to small differentiated adipocytes, which is a more
insulin-sensitive phenotype.40,41 In line with this phenotypic
change, CCL2 and PAI-1 gene expression levels in the adipose
tissue were significantly decreased after CCR2 inhibition.
These results are in contrast with a previous study using
CCL2-deficient diabetic mice.12 Chow et al.12 observed that
kidney macrophage accumulation and the progression of
diabetic renal injury were substantially reduced in CCL2-
deficient diabetic mice, but pathological changes in the
adipose tissue including macrophage accumulation was not
observed in CCL2-deficient diabetic mice. This different
result may be derived from the physiological action
mechanism of CCR2. Although the physiological action of
CCL2 occurred only through CCR2, CCR2 is a receptor for
other CCLs, including CCL8 and CCL7. Hence, CCR2
blockade may have an additional metabolic effect in the
adipose tissue while CCR2 seems to be a major receptor for
CCL2 in the kidney in mediating leukocyte recruitment. In
addition, we also observed that lipid peroxidation was
markedly decreased after CCR2 inhibition. Taken together,
these results suggest that the CCR2 antagonist RS504393
decreased inflammation and oxidative stress in the adipose
tissue, leading to improved insulin resistance.
We also found that decreased albuminuria and improve-
ment in mesangial expansion were accompanied by suppres-
sion of the synthesis of profibrotic or proinflammatory
molecules, including TGF-b1, PAI-1, type IV collagen, and
CCL2 in renal tissues. In addition, renal infiltration of
macrophages and monocytes as evaluated by CD68 staining
was reduced by CCR2 antagonist treatment. These results
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were in line with recent reports that CCL2 blockade prevents
glomerulosclerosis and improves glomerular filtration rate in
type 2 diabetic mice.42 Interestingly, the plasma level of CCL2
showed higher levels in the CCR2-treated group, whereas the
adipose tissue and renal expression of CCL2 was significantly
decreased in the CCR2 group. It has been reported that CCR2
inhibition can provide positive feedback control because
systemic levels of CCL2 were increased sevenfold in CCR2
knockout mice compared with wild-type mice.43 Given that
monocyte chemoattractant protein-1 is secreted by various
cell types, including mononuclear cells, endothelial cells, and
adipocytes, elevated plasma levels of CCL2 in this study may
be a secondary change.
In this study, we first observed that the CCR2 antagonist
RS504393 improved renal lipid metabolism and oxidative
stress in the diabetic kidney. The CCR2 antagonist markedly
suppressed the expression of mRNA levels of genes involved
in cholesterol synthesis, such as SREBP-1c, whereas ABCA-1,
which modulates cholesterol efflux, was significantly decrea-
sed by the CCR2 antagonist. This result is in agreement with
previous reports suggesting an important role for renal lipid
metabolism in the pathogenesis of diabetic nephropathy.44,45
Interestingly, CCR2 antagonist treatment improved altera-
tions of renal lipid metabolism, subsequently reducing renal
cholesterol and triglyceride content. Taken together, these
results suggest that CCR2 inhibition partially improves renal
function by improving renal lipid metabolic abnormalities.
In addition, we also observed that lipid peroxidation of renal
and adipose tissues as determined by tissue LPO levels were
significantly suppressed by CCR2 antagonist treatment.
Furthermore, plasma and urinary 8-isoprostane levels as
oxidative stress markers were also significantly decreased after
CCR2 antagonist treatment.
In conclusion, the CCR2 antagonist RS504393 provided a
protective effect against target organ damage in type 2
diabetic mice through improved metabolic alterations as well
as inhibition of profibrotic and proinflammatory processes in
the target organs. These findings suggest that CCR2
antagonism by RS504393 or other compounds may be a
novel strategy for the prevention or treatment of various
diabetic complications, including diabetic nephropathy.
MATERIALS AND METHODS
Animal experiments
Six-week-old male diabetic db/db mice (C57BLKS/J-leprdb/leprdb)
were purchased from Jackson Laboratory (Sacramento, CA, USA).
Mice were divided into two groups comprising diabetic controls and
the drug-treated diabetic group (n¼ 8 in each group). The CCR2
antagonist (RS504393) was purchased from Tocris Bioscience
(Tocris Cookson, Ellisville, MI, USA). Mice were fed either normal
chow or chow mixed with 2mg/kg per day of the CCR2 antagonist
(RS504393) for 12 weeks from 8 weeks of age. All mice were
provided with a standard diet and water and were maintained in a
temperature (23±2 1C)- and humidity-controlled (55±5%) room
with a 12-h light–dark cycle. Daily food intake was monitored at
regular intervals to confirm drug administration. In brief, we freshly
prepared a chow containing RS504393 at 2-week intervals after
calculating food intake in the CCR2-treated group. After calculation
of daily food intake, we grinded normal chow and mixed different
amounts of RS504393 based on body weight. During the experi-
ment, food intake, water intake, urine volume, body weight, fasting
plasma glucose concentration, and HbA1c levels were measured
every month. Plasma glucose levels were measured using a glucose
oxidase-based method, whereas creatinine levels were determined
using a modified Jaffe method. Plasma insulin levels and plasma
adiponectin levels were measured using an ELISA (enzyme-linked
immunosorbent assay) kit (Linco Research, St Charles, MO, USA).
The homeostasis model assessment-insulin resistance was calculated
by the equation fasting glucose (mmol/l) fasting insulin (mUnits/l)/
22.5. Plasma triglyceride and cholesterol analyses were performed
using a GPO-Trinder kit (Sigma-Aldrich, St Louis, MO, USA). Plasma
lipoprotein profiles were measured using a fast protein liquid
chromatography (high-performance liquid chromatography) system.
Plasma CCL2 levels were measured by quantitative sandwich ELISA
using a commercially available kit (Biosource, Camarillo, CA, USA).
Plasma aldosterone concentrations were measured using a radio-
immunoassay kit (Coat-A-Count kit, DPC, Los Angeles, CA, USA).
All experiments were conducted in accordance with the NIH
(National Institute of Health) guidelines and with approval of the
Korea University Institutional Animal Care and Use Committee.
We performed insulin tolerance testing and glucose tolerance test
to determine the insulin resistance state and glucose intolerance
state of each group at the end of the study. The insulin tolerance test
was conducted by an i.p. injection of 0.75Units/kg regular insulin in
fasted mice and by measuring blood glucose levels at 0, 30, 60, 90,
and 120min thereafter. The glucose tolerance test was performed by
an i.p. injection of 2 g dextrose per kilogram body weight after an
8-h fasting period, and blood samples were collected through the
tail vein. Lipids from the hepatic, adipose, and renal cortical tissues
were extracted as described by Bligh and Dyer.46 Total cholesterol
and triglyceride contents were measured using a commercial kit
(Wako Chemicals, Richmond, VA, USA) according to the manu-
facturer’s instructions. Plasma and urinary levels of 8-isoprostane
were measured using an ELISA kit (Cayman Chemical, Ann Arbor,
MI, USA). The extent of peroxidative reaction in the adipose tissue
and kidneys were determined by directly measuring LPOs using
redox reactions with ferrous ions from adipose tissue homogenates
and an LPO assay kit (Cayman Chemical) as described previously.47
To determine urinary albumin excretion, individual mice were caged
once every month in a metabolic cage and urine was collected for
24 h. Urinary albumin concentrations were determined by compe-
titive ELISA (Shibayagi, Shibukawa, Japan) after correction by
urinary creatinine concentrations.
Determination of blood pressure and cardiac function
To determine the cardiovascular effect of the drug, measurement of
systolic blood pressure and echocardiograms were performed at the
end of the study. Systolic blood pressure was measured using
prewarmed unanesthetized mice with tail-cuff plethysmography
(LE 5001-Pressure Meter, Letica SA, Barcelona, Spain) after being
acclimatized to the tail cuff for 1 week. Transthoracic echocardio-
grams were performed on unanesthetized mice. In brief, echo-
cardiograms were performed using a 13-MHz linear transducer
(Vivid 7 Ultrasound System, GE Healthcare, Pittsburgh, PA, USA).
Before initiation of the study, mice were allowed to acclimatize to
the echo probe on two separate occasions over 1–2 days. Standard
echocardiographic short- and long-axis views were obtained; LV
function, ventricular size, and wall thickness were measured from
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M-mode frames. Digital images were obtained and analyzed offline.
Fractional shortening was estimated as a systolic function from the
following formula: fractional shortening (%)¼ ((LVIDdLVIDs)/
LVIDd) 100. Similarly, LV mass index was calculated as a marker
of LV hypertrophy corrected for a 10 g body weight from the following
formula: 1.055 ((IVSdþ LVIDdþ LVPWd)3(LVIDd)3)/10 g, where
LVIDd is the LV internal dimension in diastole, LVIDs the LV internal
dimension in systole, IVSd the interventricular septal thickness in
diastole, and LVPWd the LV posterior wall thickness in diastole. After
3 months of treatment, mice were killed, and heart, epididymal fat,
liver, and kidney tissues were weighed and subsequently snap frozen in
liquid nitrogen. Mice were killed under anesthesia by an i.p. injection
of sodium pentobarbital (50mg/kg).
Histopathological evaluation and immunohistochemistry
The cardiac, aortic, pancreatic, hepatic, and adipose tissues were
fixed for 48 h with 10% paraformaldehyde at 4 1C, dehydrated,
embedded in paraffin, cut into 4-mm-thick slices, and stained with
periodic acid-Schiff, Masson’s trichrome, and hematoxylin and
eosin. The paraffin-embedded kidney slices were used for periodic
acid-Schiff, Masson’s trichrome staining, and immunohisto-
chemistry for type IV collagen, TGFb1, PAI-1, and CD68 proteins.
To determine islet hypertrophy, the total islet area was measured in
periodic acid-Schiff-stained sections using a NIH image analysis
system (Scion Image beta 4.02 Win, Bethesda, MA, USA) equipped
with digital camera through Olympus microscope (IX 81, Olympus
America, Melville, NY, USA). From more than 10 fields that were
examined under high power ( 200), the islet area was traced and
the total islet area was calculated and expressed as the average score.
To determine the medial thickness of the aorta, the thickness of
intima and media was measured using a NIH image analysis system
(Scion Image beta 4.02 Win). The intima was defined as the area
between the lumen and the internal elastic lamina. The media was
defined as the area between the internal and external elastic laminas.
Cell size of the adipose tissue was also measured in hematoxylin and
eosin-stained sections of epididymal fat tissue using a NIH image
analysis system. More than 10 fields were analyzed, and these scores
were compared in each group.
Glomerular mesangial expansion was scored semi-quantitatively,
whereby the percentage of mesangial matrix occupying each
glomerulus was rated on a scale from 0 to 4 as follows: 0, 0%; 1,
o25%; 2, 25–50%; 3, 50–75%; and 4, 475%. For immunohisto-
chemical staining, renal tissues were sliced into 4-mm-thick sections
and placed onto standard commercial microscopic slides. After
removal of the paraffin and dehydration in xylene and graded
alcohols, slides were immersed in distilled water. Next, the slides
were transferred to a 10mmol/l citrate buffer solution at pH 6.0 and
then heated at 80 1C for 30min to retrieve antigens for TGF-b1 and
CD68 staining. Alternatively, sections were transferred to a Biogenex
Retrievit (pH 8.0) (InnoGenex, San Ramon, CA, USA) and
microwaved for 10–20min for antigen retrieval before PAI-1
staining. For type IV collagen staining, slides were treated with
trypsin (1 tablet per 1ml H2O) for 20min for antigen retrieval. To
block endogenous peroxidase activity, 3.0% H2O2 in methanol was
applied for 20min after washing in water, followed by incubating
the slides at room temperature for 60min with 3% bovine serum
albumin/3% normal goat serum (type IV collagen and CD68),
15min with 10% powerblock (PAI-1), or 30min with 20% normal
sheep serum (TGF-b1). Slides were then incubated overnight at 4 1C
with a rabbit polyclonal anti-TGF-b1 antibody (1:100; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), rat monoclonal anti-CD68
antibody (1:100; AbD Serotec, Raleigh, NC, USA), a rabbit
polyclonal anti-type IV collagen antibody (1:150; BioDesign
International, Sarco, ME, USA), or rabbit polyclonal anti-PAI-1
antibody (1:60; American Diagnostica, Stamford, CT, USA). Slides
were incubated with respective secondary antibodies for 30min. For
coloration, slides were incubated at room temperature with a
mixture of 0.05% 3,30-diaminobenzidine containing 0.01% H2O2
and counterstained with Mayer’s hematoxylin. Negative control
sections were stained under identical conditions with a buffer
solution substituted for the primary antibody. For evaluation of
immunohistochemical staining for type IV collagen, TGF-b1, PAI-1
results, and glomerular fields were graded semi-quantitatively as
described previously.6 To evaluate immunohistochemical staining
for CD68 staining, the numbers of positively stained macrophages
were counted under a high-power field containing 50–60 glomeruli
and an average score was calculated and expressed as positive cells
per glomerulus. A pathologist carried out the histological examina-
tions in a blinded manner.
Analysis of gene expression by real-time quantitative PCR
Total RNA was extracted from the renal cortical tissues or the adipose
tissue with Trizol reagent and further purified using an RNeasy Mini
kit (Qiagen, Valencia, CA, USA). Primers were designed from
respective gene sequences using Primer 3 software (Whitehead
Institute, Cambridge, MA, USA) and the secondary structures of
the templates were examined and excluded using mfold software
(Rensselaer Polytechnic Institute, Troy, NY, USA). The nucleotide
sequences of all primers used in this study are shown in Table 2.
Quantitative gene expression was performed on a LightCycler 1.5
system (Roche Diagnostics Corporation, Indianapolis, IN, USA)
using SYBR Green technology. In brief, in 96-well real-time PCR
plates, 10ml SYBR Green master mix was added to 1ml of RNA
(corresponding to 50ng of total RNA) and 900 nmol/l of forward and
reverse primers in a total reaction volume of 20ml. Real-time reverse
transcriptase-PCR was performed for 10min at 50 1C and 5min at
95 1C. A total of 22–30 cycles were then applied, which consisted of
denaturation for 10 s at 95 1C and annealing with extension for 30 s at
60 1C. On completion of cycling, samples were heated to 95 1C to
verify that a single PCR product was obtained during amplification.
The ratio of each gene and b-actin level (relative gene expression
number) was calculated by subtracting the threshold cycle number
(Ct) of the target gene from that of b-actin and raising two to the
power of this difference. The specificity and confirmation of a single
clean band of each PCR product was evaluated by melting curve
analysis, followed by agarose gel electrophoresis.
Western blot analysis for SREBP-1
Next, we performed a western blot analysis for SREBP-1 from
the renal cortical tissues to further confirm the effect of CCR2
antagonist treatment. In all, 20 mg of protein was electrophoresed on
10% SDS-PAGE mini-gel under denaturing conditions. The proteins
were transferred onto a polyvinylidene difluoride membrane; the
membranes were incubated with blocking solution for 1 h at room
temperature and hybridized overnight with rabbit polyclonal anti-
SREBP-1 antibody (1:500, Santa Cruz Biotechnology) or mouse
monoclonal anti-b-actin antibody (1:5000; Sigma-Aldrich) in
blocking buffer at 4 1C. The filter was then incubated with
horseradish peroxidase-conjugated secondary antibody diluted
1:1000 for 60min at room temperature. The detection of specific
signals was performed using the enhanced chemiluminescence
method (Amersham, Buckinghamshire, UK).
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Culture and measurement of glucose uptake in adipocytes
3T3-L1 cells were obtained from the American Type Cell Culture
(ATCC, Manassas, VA, USA) and were maintained in Dulbecco’s
modified Eagle’s medium containing 10% fetal bovine serum and
100mg/ml antibiotics at 37 1C under a humidified 5% CO2
atmosphere. Differentiation of preadipocytes into adipocytes was
induced by the addition of a hormone cocktail as described
previously.48 In brief, 2 days after confluence, the medium was
replaced with standard adipocyte differentiation induction medium
containing 0.5mmol/l isobutylmethylxanthine, 1 mmol/l dexametha-
sone, and 10 mg/ml insulin. Differentiation of adipocytes was
confirmed morphologically by oil-red O-stained lipid droplets in
the cytoplasm, quantitation of intracytoplasmic lipids, and peroxi-
some proliferator-activated receptor-g expression (data not shown).
After being induced for 15 days, we next performed 2-DOG uptake
assay to define the direct effect of RS504393 on insulin sensitivity in
adipocytes. Differentiated adipocytes were starved in serum-free
medium for 24 h and then washed three times with phosphate-
buffered saline buffer. Cells were incubated in 1ml of Krebs–Ringer
phosphate Hepes buffer (136mmol/l NaCl, 4.7mmol/l KCl,
1.2mmol/l CaCl2, 2.5mmol/l Na2HPO4, 10mmol/l Hepes, and
0.1% (w/v) bovine serum albumin, pH 7.4) for 30min at 37 1C.
Cells were then stimulated with 10 nmol/l of insulin with or without
previous treatment of 100 nmol/l of RS504393 and incubated for
15min at 37 1C. Cells were next incubated with 1 mCi of 2-deoxy-
[1-3H]-D-glucose, and incubated for the indicated times from 10 to
30min. To exclude noncarrier-mediated glucose uptake, 10 mmol/l
of cytochalasin B was pretreated for 30min in control wells. At the
indicated time, the media were collected, cells washed three times
with phosphate-buffered saline buffer and lysed in 0.1 N NaOH for
1 h at room temperature. Total radioactivity from the media (Rm)
and total cell-associated radioactivity from lysates (Rc) were counted
using a liquid scintillation counter. True glucose uptake was
calculated as follows: radioactivity of glucose uptake¼
(Rc/(RmþRc))sample(Rc/(RmþRc))cytochalasin B. The radioactivity
was normalized for total protein quantified by the Bradford method.
All experimental groups were cultured in triplicate and harvested at
indicated times from 10 to 30min.
Statistical analysis
Nonparametric analysis was used because of the relatively small
number of samples present. Results were expressed as mean±s.e.m.
The Mann–Whitney U-test was used to compare two groups using a
microcomputer-assisted program with SPSS for Windows 10.0
(SPSS, Chicago, IL, USA). A significance level of 5% was chosen for
all tests (P-value¼ 0.05).
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